CN101321532B - 用于治疗神经纤维瘤病的嘧啶基氨基苯甲酰胺衍生物 - Google Patents

用于治疗神经纤维瘤病的嘧啶基氨基苯甲酰胺衍生物 Download PDF

Info

Publication number
CN101321532B
CN101321532B CN2006800456624A CN200680045662A CN101321532B CN 101321532 B CN101321532 B CN 101321532B CN 2006800456624 A CN2006800456624 A CN 2006800456624A CN 200680045662 A CN200680045662 A CN 200680045662A CN 101321532 B CN101321532 B CN 101321532B
Authority
CN
China
Prior art keywords
acid
alkyl group
amino
low alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800456624A
Other languages
English (en)
Chinese (zh)
Other versions
CN101321532A (zh
Inventor
P·W·曼雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101321532A publication Critical patent/CN101321532A/zh
Application granted granted Critical
Publication of CN101321532B publication Critical patent/CN101321532B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800456624A 2005-12-06 2006-12-05 用于治疗神经纤维瘤病的嘧啶基氨基苯甲酰胺衍生物 Expired - Fee Related CN101321532B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74278105P 2005-12-06 2005-12-06
US60/742,781 2005-12-06
PCT/EP2006/069335 WO2007065898A1 (en) 2005-12-06 2006-12-05 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis

Publications (2)

Publication Number Publication Date
CN101321532A CN101321532A (zh) 2008-12-10
CN101321532B true CN101321532B (zh) 2011-06-29

Family

ID=37831665

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800456624A Expired - Fee Related CN101321532B (zh) 2005-12-06 2006-12-05 用于治疗神经纤维瘤病的嘧啶基氨基苯甲酰胺衍生物

Country Status (13)

Country Link
US (4) US20080318988A1 (enExample)
EP (2) EP1959957B1 (enExample)
JP (4) JP2009518358A (enExample)
KR (2) KR101498848B1 (enExample)
CN (1) CN101321532B (enExample)
AU (1) AU2006323992B2 (enExample)
BR (1) BRPI0619416A2 (enExample)
CA (1) CA2629132C (enExample)
ES (2) ES2549327T3 (enExample)
PL (1) PL1959957T3 (enExample)
PT (1) PT1959957E (enExample)
RU (1) RU2450814C2 (enExample)
WO (1) WO2007065898A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2009158447A2 (en) * 2008-06-27 2009-12-30 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
KR20110053354A (ko) * 2008-08-13 2011-05-20 노파르티스 아게 폐동맥 고혈압의 치료
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BR112012009094A8 (pt) * 2009-10-23 2017-10-10 Novartis Ag método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase
JP7230817B2 (ja) 2017-10-03 2023-03-01 凸版印刷株式会社 超音波シール用アンビル及び超音波シール装置
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
WO2026035611A1 (en) * 2024-08-05 2026-02-12 Amo Pharma Ltd Methods of treating neurofibromatosis using farnesyl dibenzodiazepinones

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
PT1843771E (pt) * 2005-01-28 2011-12-02 Novartis Ag Uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação da atividade da cinase tie-2
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit

Also Published As

Publication number Publication date
BRPI0619416A2 (pt) 2011-10-04
CN101321532A (zh) 2008-12-10
US20140073660A1 (en) 2014-03-13
JP2017193553A (ja) 2017-10-26
KR20080077973A (ko) 2008-08-26
PT1959957E (pt) 2012-10-29
PL1959957T3 (pl) 2012-12-31
KR101498848B1 (ko) 2015-03-05
KR101413387B1 (ko) 2014-06-27
RU2450814C2 (ru) 2012-05-20
ES2391199T3 (es) 2012-11-22
EP2177222B1 (en) 2015-07-15
CA2629132C (en) 2014-05-27
EP1959957B1 (en) 2012-07-18
US20080318988A1 (en) 2008-12-25
EP1959957A1 (en) 2008-08-27
AU2006323992A1 (en) 2007-06-14
KR20140022431A (ko) 2014-02-24
CA2629132A1 (en) 2007-06-14
JP2015091818A (ja) 2015-05-14
EP2177222A1 (en) 2010-04-21
RU2008127264A (ru) 2010-01-20
WO2007065898A1 (en) 2007-06-14
ES2549327T3 (es) 2015-10-27
US20100234408A1 (en) 2010-09-16
JP2009518358A (ja) 2009-05-07
AU2006323992B2 (en) 2010-07-08
US8604045B2 (en) 2013-12-10
US20130123290A1 (en) 2013-05-16
JP2013107893A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
ES2274642T3 (es) Derivados de quinazolina como medicamentos.
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
EA012837B1 (ru) Производные хиназолинона в качестве ингибиторов parp
MX2013008791A (es) Metodos para usar inhibidores de alk.
JP2013189443A (ja) チロシンキナーゼ阻害剤
JP2013213042A (ja) Ｔｉｅ−２キナーゼ活性の調節に応答する疾患を処置するためのピリミジルアミノベンズアミドの使用
RU2481840C2 (ru) КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
RU2445960C2 (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
JP5751568B2 (ja) 悪性末梢神経鞘腫瘍の処置
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110629

Termination date: 20181205